1
|
Moodie LWK, Hubert M, Zhou X, Albers MF, Lundmark R, Wanrooij S, Hedberg C. Photoactivated Colibactin Probes Induce Cellular DNA Damage. Angew Chem Int Ed Engl 2018; 58:1417-1421. [DOI: 10.1002/anie.201812326] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2018] [Indexed: 12/15/2022]
Affiliation(s)
| | - Madlen Hubert
- Integrative Medical Biology; Umeå University; 90187 Umeå Sweden
| | - Xin Zhou
- Medical Biochemistry and Biophysics; Umeå University; 90187 Umeå Sweden
| | | | - Richard Lundmark
- Integrative Medical Biology; Umeå University; 90187 Umeå Sweden
- Medical Biochemistry and Biophysics; Umeå University; 90187 Umeå Sweden
| | - Sjoerd Wanrooij
- Medical Biochemistry and Biophysics; Umeå University; 90187 Umeå Sweden
| | | |
Collapse
|
2
|
Moodie LWK, Hubert M, Zhou X, Albers MF, Lundmark R, Wanrooij S, Hedberg C. Photoactivated Colibactin Probes Induce Cellular DNA Damage. Angew Chem Int Ed Engl 2018. [DOI: 10.1002/ange.201812326] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
| | - Madlen Hubert
- Integrative Medical Biology; Umeå University; 90187 Umeå Sweden
| | - Xin Zhou
- Medical Biochemistry and Biophysics; Umeå University; 90187 Umeå Sweden
| | | | - Richard Lundmark
- Integrative Medical Biology; Umeå University; 90187 Umeå Sweden
- Medical Biochemistry and Biophysics; Umeå University; 90187 Umeå Sweden
| | - Sjoerd Wanrooij
- Medical Biochemistry and Biophysics; Umeå University; 90187 Umeå Sweden
| | | |
Collapse
|
3
|
F. Tietze L, Gandamala R, Hoekman S, Kangani M, E. Nidhiry J, Penchalaiah K, Singh Raghuvanshi D. Synthesis and Biology of Dimeric, Trimeric and Tetrameric Analogues of Duocarmycin SA. HETEROCYCLES 2018. [DOI: 10.3987/com-17-s(t)16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Tranoy-Opalinski I, Legigan T, Barat R, Clarhaut J, Thomas M, Renoux B, Papot S. β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update. Eur J Med Chem 2014; 74:302-13. [PMID: 24480360 DOI: 10.1016/j.ejmech.2013.12.045] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Revised: 12/22/2013] [Accepted: 12/23/2013] [Indexed: 02/07/2023]
Abstract
The design of novel antitumor agents allowing the destruction of malignant cells while sparing healthy tissues is one of the major challenges in medicinal chemistry. In this context, the use of non-toxic prodrugs programmed to be selectively activated by beta-glucuronidase present at high concentration in the microenvironment of most solid tumors has attracted considerable attention. This review summarizes the major progresses that have been realized in this field over the past ten years. This includes the new prodrugs that have been designed to target a wide variety of anticancer drugs, the prodrugs employed in the course of a combined therapy, the dendritic glucuronide prodrugs and the concept of β-glucuronidase-responsive albumin binding prodrugs.
Collapse
Affiliation(s)
- Isabelle Tranoy-Opalinski
- Université de Poitiers, UMR-CNRS 7285, Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP), Groupe "Systèmes Moléculaires Programmés", 4 rue Michel Brunet, 86022 Poitiers, France
| | - Thibaut Legigan
- Université de Poitiers, UMR-CNRS 7285, Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP), Groupe "Systèmes Moléculaires Programmés", 4 rue Michel Brunet, 86022 Poitiers, France
| | - Romain Barat
- Université de Poitiers, UMR-CNRS 7285, Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP), Groupe "Systèmes Moléculaires Programmés", 4 rue Michel Brunet, 86022 Poitiers, France
| | - Jonathan Clarhaut
- Université de Poitiers, UMR-CNRS 7285, Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP), Groupe "Systèmes Moléculaires Programmés", 4 rue Michel Brunet, 86022 Poitiers, France; INSERM CIC 0802, CHU de Poitiers, 2 rue de la Milétrie, 86021 Poitiers, France
| | - Mikaël Thomas
- Université de Poitiers, UMR-CNRS 7285, Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP), Groupe "Systèmes Moléculaires Programmés", 4 rue Michel Brunet, 86022 Poitiers, France
| | - Brigitte Renoux
- Université de Poitiers, UMR-CNRS 7285, Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP), Groupe "Systèmes Moléculaires Programmés", 4 rue Michel Brunet, 86022 Poitiers, France
| | - Sébastien Papot
- Université de Poitiers, UMR-CNRS 7285, Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP), Groupe "Systèmes Moléculaires Programmés", 4 rue Michel Brunet, 86022 Poitiers, France.
| |
Collapse
|
5
|
Tietze LF, Sieber SA. Duocarmycin Analogues without a DNA-Binding Indole Unit Associate with Aldehyde Dehydrogenase 1A1 and not DNA: A Reply. Angew Chem Int Ed Engl 2013. [DOI: 10.1002/ange.201301923] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
6
|
Tietze LF, Sieber SA. Duocarmycin Analogues without a DNA-Binding Indole Unit Associate with Aldehyde Dehydrogenase 1A1 and not DNA: A Reply. Angew Chem Int Ed Engl 2013; 52:5447-9. [DOI: 10.1002/anie.201301923] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2013] [Indexed: 11/10/2022]
|
7
|
Chen KC, Schmuck K, Tietze LF, Roffler SR. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue. Mol Pharm 2013; 10:1773-82. [PMID: 23448264 DOI: 10.1021/mp300581u] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Conventional cancer chemotherapy is limited by systemic toxicity and poor selectivity. Tumor-selective activation of glucuronide prodrugs by beta-glucuronidase in the tumor microenvironment in a monotherapeutic approach is one promising way to increase cancer selectivity. Here we examined the cellular requirement for enzymatic activation as well as the in vivo toxicity and antitumor activity of a glucuronide prodrug of a potent duocarmycin analogue that is active at low picomolar concentrations. Prodrug activation by intracellular and extracellular beta-glucuronidase was investigated by measuring prodrug 2 cytotoxicity against human cancer cell lines that displayed different endogenous levels of beta-glucuronidase, as well as against beta-glucuronidase-deficient fibroblasts and newly established beta-glucuronidase knockdown cancer lines. In all cases, glucuronide prodrug 2 was 1000-5000 times less cytotoxic than the parent duocarmycin analogue regardless of intracellular levels of beta-glucuronidase. By contrast, cancer cells that displayed tethered beta-glucuronidase on their plasma membrane were 80-fold more sensitive to glucuronide prodrug 2, demonstrating that prodrug activation depended primarily on extracellular rather than intracellular beta-glucuronidase activity. Glucuronide prodrug 2 (2.5 mg/kg) displayed greater antitumor activity and less systemic toxicity in vivo than the clinically used drug carboplatin (50 mg/kg) to mice bearing human lung cancer xenografts. Intratumoral injection of an adenoviral vector expressing membrane-tethered beta-glucuronidase dramatically enhanced the in vivo antitumor activity of prodrug 2. Our data provide evidence that increasing extracellular beta-glucuronidase activity in the tumor microenvironment can boost the therapeutic index of a highly potent glucuronide prodrug.
Collapse
Affiliation(s)
- Kai-Chuan Chen
- Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
| | | | | | | |
Collapse
|
8
|
Tietze LF, Müller M, Duefert SC, Schmuck K, Schuberth I. Photoactivatable Prodrugs of Highly Potent Duocarmycin Analogues for a Selective Cancer Therapy. Chemistry 2012; 19:1726-31. [DOI: 10.1002/chem.201202773] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2012] [Revised: 10/24/2012] [Indexed: 12/11/2022]
|
9
|
Tietze LF, von Hof JM, Müller M, Krewer B, Schuberth I. Glycosidic prodrugs of highly potent bifunctional duocarmycin derivatives for selective treatment of cancer. Angew Chem Int Ed Engl 2011; 49:7336-9. [PMID: 20799305 DOI: 10.1002/anie.201002502] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Lutz F Tietze
- Institut für Organische und Biomolekulare Chemie, Georg-August-Universität Göttingen, Tammannstrasse 2, 37077 Göttingen, Germany.
| | | | | | | | | |
Collapse
|
10
|
Tietze LF, von Hof JM, Müller M, Krewer B, Schuberth I. Glycosidische Prodrugs hochpotenter difunktioneller Duocarmycin-Derivate für eine selektive Tumortherapie. Angew Chem Int Ed Engl 2010. [DOI: 10.1002/ange.201002502] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
11
|
Schuster HJ, Krewer B, von Hof JM, Schmuck K, Schuberth I, Alves F, Tietze LF. Synthesis of the first spacer containing prodrug of a duocarmycin analogue and determination of its biological activity. Org Biomol Chem 2010; 8:1833-42. [DOI: 10.1039/b925070k] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
12
|
Determination of the biological activity and structure activity relationships of drugs based on the highly cytotoxic duocarmycins and CC-1065. Toxins (Basel) 2009; 1:134-50. [PMID: 22069536 PMCID: PMC3202783 DOI: 10.3390/toxins1020134] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2009] [Revised: 11/28/2009] [Accepted: 12/01/2009] [Indexed: 01/17/2023] Open
Abstract
The natural antibiotics CC‑1065 and the duocarmycins are highly cytotoxic compounds which however are not suitable for cancer therapy due to their general toxicity. We have developed glycosidic prodrugs of seco-analogues of these antibiotics for a selective cancer therapy using conjugates of glycohydrolases and tumour-selective monoclonal antibodies for the liberation of the drugs from the prodrugs predominantly at the tumour site. For the determination of structure activity relationships of the different seco-drugs, experiments addressing their interaction with synthetic DNA were performed. Using electrospray mass spectrometry and high performance liquid chromatography, the experiments revealed a correlation of the stability of these drugs with their cytotoxicity in cell culture investigations. Furthermore, it was shown that the drugs bind to AT-rich regions of double-stranded DNA and the more cytotoxic drugs induce DNA fragmentation at room temperature in several of the selected DNA double-strands. Finally, an explanation for the very high cytotoxicity of CC-1065, the duocarmycins and analogous drugs is given.
Collapse
|